我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
383
104 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1885
进行中（未招募）
29
7.6%
已完成
134
35.0%
尚未招募
75
19.6%
招募中
128
33.4%
终止
3
0.8%
Unknown
8
2.1%
撤回
6
1.6%
暂无批准数据
- The phase 2 PALOMA-2 study demonstrated that subcutaneous amivantamab plus chemotherapy achieved a 76% objective response rate in patients with EGFR exon 20 insertion-mutated advanced NSCLC. - Results showed consistency with the pivotal PAPILLON study, with a clinical benefit rate of 94% and median progression-free survival of 12.2 months at 10-month follow-up. - The subcutaneous formulation offers enhanced tolerability and convenience without sacrificing efficacy compared to intravenous administration. - European Commission approval in April 2025 for subcutaneous amivantamab formulations is expected to expand clinical applicability and lead to additional regulatory approvals.
